Mycoplasmosis in Poultry: Vaccination Strategies and Control

Etiology and Pathogen Characteristics

Mycoplasmosis in poultry is primarily caused by two pathogenic species of the genus Mycoplasma: Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS). A third species, Mycoplasma meleagridis (MM), affects turkeys, and Mycoplasma iowae (MI) is associated with embryo mortality in turkeys [1]. Mycoplasma organisms are the smallest self-replicating bacteria, lacking a cell wall and possessing a trilaminar membrane composed primarily of cholesterol, which confers pleomorphism and resistance to beta-lactam antibiotics [1, 2]. The absence of a cell wall makes them susceptible to environmental desiccation and disinfectants but facilitates intimate attachment to host respiratory epithelial cells via specialized tip organelles containing adhesins such as GapA and CrmA in MG [2].

M. gallisepticum is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys [1, 3]. M. synoviae causes infectious synovitis in chickens and turkeys and has been associated with eggshell apex abnormalities (EAA) in laying hens [4]. Both species exhibit antigenic variability through phase and size variation of surface lipoproteins, enabling immune evasion and persistent infection within flocks [2, 3].

Epidemiology and Transmission

Mycoplasmosis is distributed worldwide and imposes significant economic losses through reduced egg production, decreased feed efficiency, increased mortality, and condemnations at slaughter [1, 3]. The primary route of transmission is horizontal via aerosolized respiratory droplets, direct contact, and contaminated fomites [1]. Vertical (transovarian) transmission is a critical feature of both MG and MS, allowing the infection to persist through successive generations via infected breeder flocks [1, 4]. Infected chicks hatch with the organism and shed mycoplasmas throughout their lives, establishing endemic cycles [4].

Risk factors include high stocking density, poor ventilation, concurrent viral infections (e.g., Newcastle disease virus, infectious bronchitis virus), and environmental stressors that compromise mucociliary clearance [3, 5]. Coinfections with Escherichia coli (colibacillosis) or Ornithobacterium rhinotracheale exacerbate respiratory pathology [5]. Multisite production systems and the movement of birds or eggs between sites facilitate interflock spread [1].

Clinical Signs and Pathology

Clinical manifestations vary by species, age, and the presence of secondary pathogens. In chickens infected with MG, the classic syndrome of CRD includes rales, coughing, nasal discharge, conjunctivitis, and reduced growth rates [1, 3]. In laying flocks, egg production drops by 10–20% and eggshell quality deteriorates [3]. Turkeys with MG develop infectious sinusitis characterized by infraorbital sinus swelling, dyspnea, and frothy ocular discharge [1].

M. synoviae primarily induces lameness, swollen joints (hock and wing joints), and breast blisters in broilers and turkeys [4]. In layers, MS infection can cause EAA, where eggs exhibit rough, thin, or cracked shells at the apex, resulting from infection of the oviduct epithelium [4, 6]. Mortality is generally low in uncomplicated cases but can rise sharply when secondary bacterial infections occur [5].

Pathological lesions in MG-affected birds include catarrhal to fibrinous airsacculitis, tracheitis, and pneumonia [1, 3]. In MS synovitis, the main findings are tenosynovitis, synovial membrane thickening, and purulent to caseous exudate in joint cavities [4]. Systemic amyloidosis has been reported in chronic MS cases [6].

Diagnostic Approaches

Definitive diagnosis relies on a combination of clinical signs, serological testing, molecular detection, and culture [1, 7].

Serological methods include the rapid serum agglutination (RSA) test, hemagglutination inhibition (HI) test, and enzyme-linked immunosorbent assay (ELISA) [1, 7]. RSA is widely used as a screening tool due to its speed and low cost, but nonspecific reactions can occur [7]. HI and ELISA provide greater specificity and are preferred for confirmatory testing and surveillance [7].

Molecular detection by polymerase chain reaction (PCR) targeting species-specific genes (e.g., mgc2 for MG, vlhA for MS) offers high sensitivity and rapid turnaround [7, 8]. Real-time PCR (qPCR) allows quantification and is now standard in diagnostic laboratories [8]. Loop-mediated isothermal amplification (LAMP) assays have been developed for field use [8].

Culture requires specialized mycoplasma media (e.g., Frey's broth or agar) and incubation under microaerophilic conditions for 7–14 days [1]. Isolation is definitive but time-consuming and technically demanding [1, 7].

Serotyping and genotyping of isolates via gene sequencing (e.g., surface protein genes) is used for epidemiological tracking and vaccine strain selection [2, 8].

A summary of diagnostic methods is provided in Table 1.

Table 1: Diagnostic Methods for Avian Mycoplasmosis

Vaccination Strategies

The development and application of a poultry mycoplasma vaccine is a cornerstone of control in endemic regions and high-density production systems [1, 9]. Vaccination aims to reduce clinical signs, limit shedding, and prevent vertical transmission [9]. The two main categories are live attenuated vaccines and inactivated (killed) vaccines.

Live Attenuated Vaccines

Live vaccines are derived from field or laboratory strains that have been passaged to reduce virulence while preserving immunogenicity [9]. The most widely used MG live vaccine strains include F strain (mildly virulent, used in layers), ts-11 (temperature-sensitive, used in layers and breeders), and 6/85 (apathogenic, used in layers and broilers) [9, 10]. Each strain has distinct characteristics:

• F strain colonizes well and displaces wild-type MG but retains residual pathogenicity and can cause mild lesions in turkeys [9].
• ts-11 is temperature-sensitive, replicating only at lower body temperatures of the upper respiratory tract, providing strong protection without spread to internal organs [10].
• 6/85 is highly attenuated and safe for broilers, but its immunogenicity is lower, sometimes requiring booster doses [9].

For MS, the live vaccine strain MS-H (attenuated from a pathogenic Australian isolate) provides protection against respiratory and synovial disease and reduces eggshell apex abnormalities [4, 10]. Vaccination is typically administered via coarse spray or drinking water to day-old chicks or pullets [1, 9].

Inactivated Vaccines

Killed, oil-adjuvanted bacterins are used in breeder flocks to boost antibody titers in hens, thereby enhancing passive protection of progeny via maternal antibodies [1, 9]. Inactivated vaccines do not prevent infection but reduce clinical severity and egg transmission [9]. They are often used as a booster following live priming (prime-boost strategy) [1, 10].

Autogenous Vaccines

In flocks infected with antigenically distinct field strains, autogenous (farm-specific) bacterins can be prepared from local isolates under veterinary supervision [9]. These are used when standard vaccines fail to provide adequate protection [1].

A decision tree for vaccine selection is presented in Figure 1.

graph TD
    A[Farm Type], > B{Layers/Breeders?}
    B, >|Yes| C[Endemic MG/MS?]
    B, >|No| D[Broilers?]
    C, >|Yes| E[Live vaccine: F, ts-11, or MS-H]
    C, >|No| F[Inactivated bacterin for breeders]
    D, > G[High risk area?]
    G, >|Yes| H[Live vaccine: 6/85 or MS-H (spray)]
    G, >|No| I[No vaccination – focus on biosecurity]
    E, > J[Monitor serology and shedding]
    F, > J
    H, > J

Figure 1: Decision tree for poultry mycoplasma vaccine selection based on flock type and endemic status.

Factors Affecting Vaccine Efficacy

Efficacy depends on proper administration, timing, strain matching, and flock health [9, 10]. Concurrent immunosuppressive diseases (e.g., infectious bursal disease, Marek's disease) impair response [1]. Vaccine strains must be stored and handled according to manufacturer instructions to maintain viability [9]. Shedding of live vaccine strains can occur; thus, careful coordination is needed to avoid spread to unvaccinated or naïve flocks [10].

Control and Eradication Programs

Integrated control of mycoplasmosis relies on a combination of biosecurity, management, vaccination, and antimicrobial therapy [1, 3].

Biosecurity Measures

• Multi-site production and all-in/all-out management reduce pathogen carryover between flocks [1].
• Rodent and wild bird control prevents introduction of mycoplasmas [3].
• Quarantine and testing of replacement stock (e.g., serological monitoring of incoming pullets) is essential [7].
• Disinfection protocols using quaternary ammonium compounds or phenolic disinfectants effectively inactivate mycoplasmas [1].

Antimicrobial Treatment

Although vaccination reduces reliance on antibiotics, antimicrobials remain a tool for therapeutic and metaphylactic use. Macrolides (tylosin, tilmicosin, tiamulin, and enrofloxacin) are effective, but resistance has been reported [5, 11]. In ovo injection of antibiotics has been used to reduce vertical transmission, but this practice is controversial due to selection pressure for resistance [1]. Withdrawal periods must be observed for meat and eggs [5].

Eradication in Breeder Flocks

Official control programs, such as the National Poultry Improvement Plan (NPIP) in the United States, aim to eliminate MG and MS from primary breeder flocks [1]. These programs rely on serological monitoring, removal of positive birds, and strict biosecurity [1, 7]. Vaccination is not permitted in NPIP-certified MG-clean flocks, as it interferes with serosurveillance [9]. Eradication is feasible in geographically isolated or closed flocks but difficult in multi-age commercial complexes [1, 7].

Management of Infected Flocks

In endemic situations, vaccination is combined with optimization of housing conditions: reducing ammonia levels, improving ventilation, and minimizing stocking density [3, 5]. Nutritional support with vitamins A and E may enhance epithelial integrity and immune function [3].

Conclusion

Mycoplasmosis caused by M. gallisepticum and M. synoviae remains a major threat to poultry health and productivity worldwide. Successful control requires a multidimensional approach: rigorous biosecurity to prevent introduction and spread, accurate diagnostic surveillance to detect subclinical carriers, strategic use of poultry mycoplasma vaccine (live attenuated or inactivated) to reduce clinical impact, and judicious antimicrobial therapy when needed. Eradication programs targeting breeder flocks have demonstrated that mycoplasmosis can be eliminated from defined populations. Ongoing research into improved vaccines, rapid point-of-care diagnostics, and alternative control measures such as probiotics and bacteriophage therapy will further strengthen our ability to manage these persistent pathogens.

References

[1] Ley DH, Yoder HW Jr. Mycoplasma gallisepticum infection. In: Swayne DE, editor. Diseases of Poultry. 14th ed. Wiley-Blackwell; 2020. p. 875–911.

[2] Rosengarten R, Citti C, Glew M, et al. Host-pathogen interactions in mycoplasma pathogenesis: virulence factors and identification of protective antigens. In: Stipkovits L, Bencina D, editors. Mycoplasmas of Ruminants and Poultry. COST Action 826. European Commission; 1998. p. 29–36.

[3] Kleven SH. Mycoplasma gallisepticum infection. In: Saif YM, editor. Diseases of Poultry. 11th ed. Iowa State Press; 2003. p. 722–744.

[4] Noormohammadi AH. Mycoplasma synoviae infection in chickens and turkeys. In: Swayne DE, editor. Diseases of Poultry. 14th ed. Wiley-Blackwell; 2020. p. 912–937.

[5] Gross WB. Respiratory disease complex of chickens. In: Calnek BW, editor. Diseases of Poultry. 10th ed. Iowa State University Press; 1997. p. 297–305.

[6] Feberwee A, de Wit JJ, Landman WJM. Induction of eggshell apex abnormalities by Mycoplasma synoviae: field and experimental studies. Avian Pathol. 2009;38(1):57–66.

[7] Marois C, Pourquier P, Kempf I. Detection of Mycoplasma gallisepticum and Mycoplasma synoviae by real-time PCR and comparison with serological tests. Vet Microbiol. 2002;89(1):59–68.

[8] Raviv Z, Callison SA, Ferguson-Noel N, et al. The Mycoplasma gallisepticum gene mgc2 is a target for molecular diagnostics and typing. Avian Dis. 2007;51(2):467–473.

[9] Whithear KG. Control of avian mycoplasmoses by vaccination. Rev Sci Tech. 1996;15(4):1527–1553.

[10] Leigh SA, Branton SL, Evans JD, et al. Effects of temperature-sensitive ts-11 strain of Mycoplasma gallisepticum on layer performance. Poult Sci. 2008;87(11):2204–2209.

[11] Kempf I, Gesbert F, Guittet M, et al. Efficacy of tilmicosin in the treatment of Mycoplasma gallisepticum infection in chickens. Avian Dis. 1995;39(3):516–523. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.